Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

BACKGROUND: Peginterferon beta-1a and glatiramer acetate (GA) are approved first-line therapies for the treatment of relapsing forms of multiple sclerosis, but their therapeutic efficacy has not been compared directly. METHODS: Clinical outcomes at 2 years, including no evidence of disease activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Thomas F., Su, Ray, Xiong, Kuangnan, Altincatal, Arman, Castrillo-Viguera, Carmen, Naylor, Maria L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809527/
https://www.ncbi.nlm.nih.gov/pubmed/33488773
http://dx.doi.org/10.1177/1756286420975916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809527/
https://www.ncbi.nlm.nih.gov/pubmed/33488773
http://dx.doi.org/10.1177/1756286420975916

Ejemplares similares